A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis

PLoS Neglected Tropical Diseases

Volumn 7, Issue 11, 2013, Pages

  Krentel, Alison ^a,b   Fischer, Peter U ^a   Weil, Gary J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT;

ARTICLE; AWARENESS; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH HAZARD; HEALTH PROGRAM; HUMAN; IATROGENIC DISEASE; KNOWLEDGE; LYMPHATIC FILARIASIS; MASS DRUG ADMINISTRATION; NEGLECTED DISEASE; PATIENT COMPLIANCE; PROTOCOL COMPLIANCE;

ANIMALS; CHEMOPREVENTION; DRUG THERAPY; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS; MEDICATION ADHERENCE;

EID: 84888215613     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002447     Document Type: Article

References (89)

1. WHO (2011) Global programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 86: 377-388.
2. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, et al. (2007) Control of neglected tropical diseases. New Engl J Med 357: 1018-1027.
3. Hotez PJ, Fenwick A, Savioli L, Molyneux D, (2009) Rescuing the bottom billion through control of neglected diseases. Lancet 373: 1570-1575.
4. Zeldenryk LM, Gray M, Speare R, Gordon S, Melrose W, (2011) The emerging story of disability associated with lymphatic filariasis: a critical review. PLoS Negl Trop Dis 5: e1366 doi:10.1371/journal.pntd.0001366.
5. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G, (2007) Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis. PLoS Negl Trop Dis 1: e128 doi:10.1371/journal.pntd.0000128.
6. (1997) Elimination of lymphatic filariasis as a public health problem. Document WHA50/1997/REC/1.
7. Ottesen EA, Duke BO, Karam M, Behbehani K, (1997) Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75: 491-503.
8. Ottesen EA, (2000) The global programme to eliminate lymphatic filarisis. Trop Med Int Health 5: 591-594.
9. WHO (2012) Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiol Rec 87: 346-356.
10. Partono F, Maizels RM, Purnomo, (1989) Towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. Trans R Soc Trop Med Hyg 83: 821-826.
11. Babu B, Kar SK, (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 702-709.
12. Lahariya C, Mishra A, (2008) Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study. J Vector Borne Dis 45: 313-320.
13. Ramaiah KD, Vijay Kumar KN, Hosein E, Krishnamoorthy P, Augustin DJ, et al. (2006) A campaign of 'communication for behavioural impact' to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. Ann Trop Med Parasitol 100: 345-361.
14. Ranganath BG, (2010) Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India. J Vector Borne Dis 47: 61-64.
15. Fraser M, Taleo G, Taleo F, Yaviong J, Amos M, et al. (2005) Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. Am J Trop Med Hyg 73: 753-758.
16. Babu BV, Satyanarayana K, (2003) Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Trop Doct 33: 79-82.
17. Showkath Ali MK, Rajendran R, Regu K, Mohanan MK, Dhariwal AC, et al. (2007) Study on the factors affecting the MDA programme in Kerala state. J Commun Dis 39: 51-56.
18. Weerasooriya MV, Yahathugoda CT, Wickramasinghe D, Gunawardena KN, Dharmadasa RA, et al. (2007) Social mobilisation, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka. Filaria J 6: 11.
19. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, et al. (2000) A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 5: 842-847.
20. Sunish IP, Rajendran R, Mani TR, Gajanana A, Reuben R, et al. (2003) Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis. Trop Med Int Health 8: 316-321.
21. Anthony G, Deming M, Dorkenoo AM, Morgah K, Verani J, et al. (2009) The integration of neglected diseases: three years of experience in Togo. Am J Trop Med Hyg 81: 327-328.
22. Babu BV, Mishra S, (2008) Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans Roy Soc Trop Med Hyg 102: 1207-1213.
23. Boyd A, Won KY, McClintock SK, Donovan CV, Laney SJ, et al. (2010) A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti. PLoS Negl Trop Dis 4: e640 doi:10.1371/journal.pntd.0000640.
24. Cantey PT, Rao G, Rout J, Fox LM, (2010) Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 15: 224-231.
25. Cantey PT, Rout J, Rao G, Williamson J, Fox LM, (2010) Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis 4: e728 doi:10.1371/journal.pntd.0000728.
26. Gunawardena S, Ismail M, Bradley M, Karunaweera N, (2007) Factors influencing drug compliance in the mass drug administration programme against filariasis in the Western province of Sri Lanka. Trans R Soc Trop Med Hyg 101: 445-453.
27. Mathieu E, Direny AN, Beau de Rochars M, Streit TG, Addiss DG, et al. (2006) Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11: 862-868.
28. Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, et al. (2004) Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 98: 703-714.
29. Mitjà O, Paru R, Hays R, Griffin L, Laban N, et al. (2011) The impact of a filariasis control program on Lihir Island, Papua New Guinea. PLoS Negl Trop Dis 5: e1286 doi:10.1371/journal.pntd.0001286.
30. Regu K, Showkath Ali MK, Rajendran R, Koya SM, Ganesh B, et al. (2006) Mass drug administration against lymphatic filariasis: experiences from Kozhikode district of Kerala State. J Commun Dis 38: 333-338.
31. Ray Karmakar P, Mitra K, Chatterjee A, Jana PK, Bhattacharya S, et al. (2011) A study on coverage, compliance and awareness about mass drug administration for elimination of lymphatic filariasis in a district of West Bengal, India. J Vector Borne Dis 48: 101-104.
32. Das PK, Pani SP, Krishnamoorthy K, (2002) Prospects of elimination of lymphatic filariasis in India. ICMR Bulletin 32: 14.
33. Amarillo ML, Belizario VY Jr, Sadiang-Abay JT, Sison SA, Dayag AM, (2008) Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasit Vectors 1: 14.
34. Wamae N, Njenga SM, Kisingu WM, Muthigani PW, Kiiru K, (2006) Community-directed treatment of lymphatic filariasis in Kenya and its role in the national programmes for elimination of lymphatic filariasis. Afr J Health Sci 13: 69-79.
35. Mohammed KA, Molyneux DH, Albonico M, Rio F, (2006) Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol 22: 340-344.
36. Ramaiah KD, Vijay Kumar KN, Chandrakala AV, Augustin DJ, Appavoo NC, et al. (2001) Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 6: 1062-1069.
37. Nujum ZT, (2011) Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India. International Health (RSTMH) 3: 22-26.
38. Mahalakshmy T, Kalaiselvan G, Parmar J, Dongre A, (2010) Coverage and compliance to diethylcarbamazine in relation to Filaria Prevention Assistants in rural Puducherry, India. J Vector Borne Dis 47: 113-115.
39. Nandha B, Sadanandane C, Jambulingam P, Das P, (2007) Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, South India: 5 years of experience. Filaria J 6: 7.
40. Gyapong M, Gyapong JO, Owusu-Banahene G, (2001) Community-directed treatment: the way forward to eliminating lymphatic filariasis as a public-health problem in Ghana. Ann Trop Med Parasitol 95: 77-86.
41. King JD, Zielinski-Gutierrez E, Pa'au M, Lammie P, (2011) Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Trop 120S: S48-S54.
42. Aswathy S, Beteena K, Leelamoni K, (2009) Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala. Ann Trop Med Parasitol 103: 617-624.
43. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Ngure PK, Njenga SM, (2012) Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. South Afr J Epidemiol Infect 27: 66-70.
44. Babu BV, (2010) A qualitative study on the adverse reactions of mass treatment for lymphatic filariasis in Orissa, India. Asian Pacific J Trop Med 3: 55-58.
45. Babu BV, Nath N, (2004) The programme to eliminate lymphatic filariasis in Orissa, India: the attitudes of some programme partners. Ann Trop Med Parasitol 98: 751-757.
46. Kerketta AS, Babu BV, (2009) Clinician's attitude on mass drug administration under the program to eliminate lymphatic filariasis: a qualitative study from Orissa, India. Asia Pac J Public Health 21: 112-117.
47. El-Setouhy M, Elaziz KMA, Helmy H, Farid HA, Kamal HA, et al. (2007) The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 77: 1069-1073.
48. Njomo D, Nyamongo M, Njenfa S, Magambo J, (2010) Socio-economic and behavioural factors that influence compliance with mass treatment in the national programme for elimination of lymphatic filariasis in Kenya. Am J Trop Med Hyg 83: 67-67.
49. Rajendran R, Sunish IP, Mani TR, Munirathinam A, Abdullah SM, et al. (2002) The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia. Ann Trop Med Parasitol 96: 595-602.
50. Sapak P, Melrose W, Durrheim D, Pawa F, Wynd S,et al. (2004) Evaluation of the lymphatic filariasis control program Samarai Murua District, Papua New Guinea. Warwick, Queensland: Warwick Educational Publishing.
51. Cantey PT, Rao G, Rout J, Jolly A, Williamson J, et al. (2009) Increased adherence to mass drug administration for lymphatic filariasis- Orissa State, India, 2009. Am J Trop Med Hyg 91: 293-294.
52. Hodges MH, Smith SJ, Fussum D, Koroma JB, Conteh A, et al. (2012) High coverage of mass drug administration for lymphatic filariasis in rural and non-rural settings in the Western Area, Sierra Leone. Parasit Vectors 3: 120.
53. Vaishnav KG, Patel IC, (2006) Independent assessment of Mass Drug Administration in filariasis affected Surat city. J Commun Dis 38: 149-154.
54. Njomo DW, Amuyunzu-Nyamongo M, Mukoko DA, Magambo JK, Njenga SM, (2012) Socioeconomic factors associated with compliance with mass drug administration for lymphatic filariasis elimination in Kenya: descriptive study results. Ann Trop Med PH 5: 103-110.
55. Ramaiah KD, Vijay Kumar KN, Ravi R, Das PK, (2005) Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Ann Trop Med Parasitol 99: 243-252.
56. Mackenzie CD, Lazarus WM, Mwakitalu ME, Mwingira U, Malecela MN, (2009) Lymphatic filariasis: patients and the global elimination programme. Ann Trop Med Parasitol 103: S41-S51.
57. Krentel A, Fischer P, Manoempil P, Supali T, Servais G, et al. (2006) Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia. Trop Med Int Health 11: 1731-1740.
58. Njomo DW, Amuyunzu-Nyamongo M, Mukoko DA, Magambo JK, Njenga SM, (2012) Social mobilization and compliance with mass treatment for lymphatic filariasis elimination in Kenya. Afr J Health Sci 20: 42-49.
59. Kumar A, Kumar P, Nagaraj K, Nayak D, Ashok L, et al. (2009) A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J Vector Borne Dis 46: 237-240.
60. Pattanshetty S, Kumar A, Kumar R, Rao CR, Badiger S, et al. (2010) Mass drug administration to eliminate lymphatic filariasis in Southern India. AMJ 3: 847-850.
61. Kasturiratne KT, Premaratne BA, Pathmeswaran A, de Silva NR, de Silva HJ, (2001) Compliance with the mass chemotherapy program for lymphatic filariasis. Ceylon Med J 46: 126-129.
62. Krentel A, Aunger R, (2011) Causal chain mapping: a novel method to analyse treatment compliance decisions relating to lymphatic filariasis elimination in Alor, Indonesia. Health Policy Plan pp. 384-395.
63. Showkath AM, Regu K, Rajendran R, Mohanan MK, Ganesh B, (2008) Awareness of health personnel about lymphatic filariasis and mass drug administration in Kerala State. J Commun Diseases 40: 37-40.
64. Ramaiah KD, Ravi R, Das PK, (2005) Preventing confusion about side effects in a campaign to eliminate lymphatic filariasis. Trends Parasitol 21: 307-308.
65. Babu BV, Satyanarayana K, (2003) Healthcare workers' knowledge of lymphatic filariasis and its control in an endemic area of Eastern India: implications on control programme. Trop Doct 33: 41-42.
66. Bhullar N, Maikere J, (2010) Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia. Parasit Vectors 3: 70.
67. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. New Engl J Med 347: 1841-1848.
68. Vanamail P, Ramaiah KD, Subramanian S, Pani SP, Yuvaraj J, et al. (2005) Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India. Ann Trop Med Parasitol 99: 237-242.
69. de Rochars MB, Direny AN, Roberts JM, Addiss DG, Radday J, et al. (2004) Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg 71: 466-470.
70. Mani TR, Rajendran R, Munirathinam A, Sunish IP, Md Abdullah S, et al. (2002) Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India. Trop Med Int Health 7: 541-548.
71. Talbot JT, Viall A, Direny A, de Rochars MB, Addiss D, et al. (2008) Predictors of compliance in mass drug administration for the treatment and prevention of lymphatic filariasis in Leogane, Haiti. Am J Trop Med Hyg 78: 283-288.
72. Babu BV, Behera DK, Kerketta AS, Mishra S, Rath K, et al. (2006) Use of an inclusive-partnership strategy in urban areas of Orissa, India, to increase compliance in a mass drug administration for the control of lymphatic filariasis. Ann Trop Med Parasitol 100: 621-630.
73. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, et al. (2008) The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis 2: e344 doi:10.1371/journal.pntd.0000344.
74. Wynd S, Durrheim DN, Carron J, Selve B, Chaine JP, et al. (2007) Socio-cultural insights and lymphatic filariasis control- lessons from the Pacific. Filaria J 6: 1-4.
75. Gunawardena GS, Ismail MM, Bradley MH, Karunaweera ND, (2007) Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka. Ann Trop Med Parasitol 101: 335-341.
76. Stolk WA, de Vlas SJ, Borsboom GJ, Habbema JD, (2008) LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology 135: 1583-1598.
77. Mand S, Debrah AY, Klarmann U, Batsa L, Marfo-Debrekyei Y, et al. (2012) Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial. Clin Infect Dis 55: 621-630.
78. Wynd S, Melrose WD, Durrheim DN, Carron J, Gyapong M, (2007) Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature. Bull World Health Organ 85: 493-498.
79. Hochberg N, Michel MC, Lammie PJ, Mathieu E, Direny AN, et al. (2006) Symptoms reported after mass drug administration for lymphatic filariasis in Leogane, Haiti. Am J Trop Med Hyg 75: 928-932.
80. Hotez PJ, Fenwick A, Savioli L, Molyneux DH, (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570-1575.
81. Wijesinghe RS, Wickremasinghe AR, Ekanayake S, Perera MS, (2007) Physical disability and psychosocial impact due to chronic filarial lymphoedema in Sri Lanka. Filaria J 6: 4.
82. Litt E, Baker MC, Molyneux D, (2012) Neglected tropical diseases and mental health: a perspective on comorbidity. Trend Parasitol 28: 195-201.
83. Molyneux DH, Malecela MN, (2011) Neglected tropical diseases and the millennium development goals-why the "other diseases" matter: reality versus rhetoric. Parasit Vectors 4: 234.
84. WHO (2011) Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. Geneva, Switzerland.
85. Smits HL, (2009) Prospects for the control of neglected tropical diseases by mass drug administration. Expert Rev Anti Infect Ther 7: 37-56.
86. www.unitedtocombatntds.org (2013) From promises to progress: the first annual report on the London Declaration on NTDs. Available: http://www.unitingtocombatntds.org/reports/promises-to-progress-EN.pdf. Accessed 30 October 2013.
87. Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, et al. (2008) Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg 79: 480-484.
88. Michael E, Malecela-Lazaro MN, Maegga BT, Fischer P, Kazura JW, (2006) Mathematical models and lymphatic filariasis control: monitoring and evaluating interventions. Trends Parasitol 22: 529-535.
89. Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, et al. (2013) Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis 7: e1984 doi:10.1371/journal.pntd.0001984.